RXRX 8-K 2026-09-21

RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K dated 2026-09-21 — accession 0001601830-26-000112. This URL is the filing, not the RXRX hub.

RECURSION PHARMACEUTICALS, INC. (RXRX) is a biotechnology company listed on NASDAQ.

RECURSION PHARMACEUTICALS, INC. filed a 8-K on 2026-09-21. Accession 0001601830-26-000112.

Cached items: 1.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported RXRX revenue for 2025-12-31 was $74.7M. Net income was -$644.8M. Revenue was up 26.9% from 2024-12-31 to 2025-12-31. RXRX currently screens at market cap $1.75B.

Not investment advice. The RXRX SEC hub lists recent forms. The stock page is the research view.